TheEdgeResearch
Home / Stocks / BGT.AX

Bio-Gene Technology Limited (BGT.AX)

ASX Basic Materials Agricultural Inputs
$0.02 ▲ +0.00%
Market Cap
$5.9M
Sector
Basic Materials
Industry
Agricultural Inputs
Beta
0.78
52-Wk Range
0.016-0.061
CEO
Timothy Owen Grogan
Country
AU
Currency
AUD

Bio-Gene Technology Limited operates in the Agricultural Inputs industry of the Basic Materials sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $5.9M. Its beta of 0.78 implies it has historically moved less than the broad market.

Company profile
Exchange
Australian Securities Exchange
Employees
5
IPO date
2017-11-28
Headquarters
Melbourne, VIC, AU
About Bio-Gene Technology Limited

Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop protection, public health, and consumer applications. The company's key products include Flavocide, an insecticide utilizing beta-triketone technology, and Qcide, a natural oil derived from a specific cultivar of eucalyptus cloeziana. Bio-Gene maintains a research partnership with James Cook University to develop a tissue culture system, a critical step for expanding tree plantations and increasing future Qcide oil production. Furthermore, the company collaborates with BASF, the Grains Research and Development Corporation, and the Queensland Department of Agriculture and Fisheries to assess its products' effectiveness against grain storage pests. Established in 1995, Bio-Gene Technology Limited operates from its headquarters in Melbourne, Australia.

Comparable companies

Bio-Gene Technology Limited is most often compared with the following Basic Materials names:

ACR.AXBIT.AXCAN.AXCHM.AXICR.AXIRX.AXIXC.AXMEM.AXPER.AXVBS.AX
More research on BGT.AX
BGT.AX technical analysis BGT.AX TheEdge Score Compare against peers
Open full interactive analysis & DCF →